Login to Your Account



Pharma: Clinic Roundup


Thursday, May 24, 2012

• Shire plc, of Dublin, Ireland, reported Phase III results demonstrating the long-term maintenance efficacy of lisdexamfetamine dimesylate (LDX) in children and adolescents, ages 6 to 17, with attention deficit hyperactivity disorder (ADHD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription